The laboratory developed test performed on a real-time PCR platform to detect Rhesus D (RhD) incompatibility will be marketed by Sequenom’s nonexclusive licensee, CLIA-certified, Lenetix Medical Screening Laboratory based at Mineola, New York.
The company expects to introduce additional noninvasive prenatal tests, beginning in the first half of 2008 with a LDT application for fetal(XY)/gender screening, which may assist healthcare providers in the evaluation of high risk pregnancies with familial history of inherited disorders associated with the X chromosome.
Harry Stylli, president and CEO of Sequenom, said: “This will be the first commercially introduced noninvasive prenatal test in the US to utilize the SEQureDx technology and represents a significant step in our strategy.”